Sophia Genetics SA Form 4 insider transactions

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 12, 2026 for $7.52 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 shares of common stock on August 13, 2026 for $7.52 per share.

Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 7, 2026 for $7.60 per share.

Jurgi Camblong, Executive Chairman and a Director of SOPHiA GENETICS SA, sold 28,500 shares of common stock on August 7, 2026.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 20,000 shares of common stock on August 5, 2026.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on July 27, 2026 for $5.66 per share.

Jurgi Camblong, Executive Chairman and a Director of SOPHiA GENETICS SA, sold 44,381 shares of common stock on July 20, 2026.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on July 13, 2026 for $5.70 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 shares of common stock on July 13, 2026 for $5.70 per share.

Jurgi Camblong, Executive Chairman and a Director of SOPHiA GENETICS SA, sold 8,500 shares of common stock on July 10, 2026 for $5.62 per share.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong sold 17,685 ordinary shares to cover tax obligations related to vested restricted stock units, executing the sale under a pre-arranged Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief Financial Officer George Cardoza sold 1,592 ordinary shares to cover tax withholding obligations related to vested RSUs, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS SA reports a Form 4 filing detailing a Chief People Officer's sale of ordinary shares to cover tax obligations, executed under a pre-arranged trading plan.

Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 5,285 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 7,393 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that CEO Ross Muken sold 9,838 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS SA reports a Form 4 filing detailing Chief Sales Officer Kevin Puylaert's sale of ordinary shares to cover tax liabilities related to vesting restricted stock units.

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported a sale of 7,393 ordinary shares on July 6, 2026, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA Executive Chairman Jurgi Camblong sold 22,486 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS SA, executed a Rule 10b5-1 trading plan, resulting in the sale of ordinary shares and the exercise of stock options.

SOPHIA GENETICS SA's Chief Technology Officer, Abhimanyu Verma, sold 6,944 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports a Form 4 filing detailing a transaction by Chief Medical Officer Philippe Menu.

SOPHIA GENETICS SA reports a Form 4 filing detailing a transaction by Chief Scientific Officer Zhenyu Xu.

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported a sale of 5,000 ordinary shares under a pre-arranged trading plan.

SOPHiA GENETICS SA CEO Jurgi Camblong reported the sale of 8,500 ordinary shares for $5.2354 per share, executed under a pre-arranged trading plan.

SOPHiA GENETICS SA's Chief Financial Officer, George Cardoza, purchased 20,000 ordinary shares at $4.95 each, signaling confidence.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported a sale of 5,000 ordinary shares.

SOPHIA GENETICS SA reports that President Ross Muken sold 761 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 608 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA CEO Jurgi Camblong sold 4,486 ordinary shares to cover tax obligations related to restricted stock unit vesting, executed under a Rule 10b5-1 trading plan.